Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

Lebrikizumab, a monoclonal antibody that inhibits an interleukin named IL-13, is especially promising in treatment of this disease. Having been in development by Almirall and Eli Lilly and Company ...

Problems at a contract manufacturing organisation have scuppered Eli Lilly’s hopes of a timely FDA approval for lebrikizumab, its IL-13 inhibitor for the treatment of atopic dermatitis or eczema.

The launch of Almirall’s eczema treatment, Ebglyss (lebrikizumab), generated $22 million in sales across initial European markets, while Ilumetri (tildrakizumab) for psoriasis saw sales rise 24.8% ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...

Eli Lilly shares fell sharply in early Wednesday trading after the pharmaceutical giant posted weaker-than-expected third-quarter earnings, while slashing its full-year profit forecast, following ...

Over the last 3 months, EPS estimates have seen 0 upward revisions and 13 downward. Revenue estimates have seen 16 upward ...

BTIG raised the firm’s price target on Apogee Therapeutics (APGE) to $100 from $81 and keeps a Buy rating on the shares. Eli Lilly (LLY) ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

Thomas Bieber, University of Bonn, Germany, wasted no time in welcoming his colleagues from around the world to the ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

“Eli Lilly is positioned well among the large biopharma companies, with no major LoEs approaching and durable growth behind blockbuster products Mounjaro, Verzenio, and lebrikizumab. We think ...